becton dickinson co march
becton dickinson co
bard integr expect bring revenu
maintain buy rate bd upgrad tp
perviou tp deriv
tp base non ep forward price-to-earnings
provid upsid potenti
expect top-lin revenu growth
respect
compani perform well consid new product
launch segment continu double-digit
growth emerg market achiev carefus
cost synergi end expect achiev
remain cost synergi carefus end
bard integr drive revenu
intervent segment expand vascular portfolio
success integr bard activ
track day expand access
vascular portfolio expect achiev
revenu growth expect achiev cost
synergi end
plan launch new product segment
within medic segment recent begun
ship iv solut custom partnership
freseniu
expect continu target expans bd menu
fiscal year launch enter viral panel tb
assay addit anticip approv bd onclar
hpv assay differenti women health
end decemb upon close bard transact
compani gross debt leverag time expect
begin de-lev latter half fiscal
compani namebecton dickinson companytickerbdxstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispidearavindra becton dickinson co ch
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co march
invest standpoint plan invest
toward bard revenu synergi dilut
earn basi point
total first quarter revenu billion grew
currency-neutr basi result includ impact
 dispens chang lower total
compani revenu growth basi point exclud
impact drove revenu growth
geograph wise revenu increas
billion compar prior year
period revenu
billion increas prior-year
period currency-neutr basi emerg
market revenu million compar
million prior year quarter
averag price-to-earnings price-to-earnings till date
expect fall
price-to-earnings averag
price-to-earnings move averag
saw good growth busi new product
launch innov stock achiev
growth last one year expect acquisit bard
drive revenu
maintain buy rate target price
gross margin increas quarter
roa roe quarter
ep
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date dec ex-dividend date dec last split factor new per last split date aug inform becton dickinson co march
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co march
non- reconcili refer pg
incom statement month end month end month end month end month end month end month end month end month end month end month end revenu total- total revenu gross selling/general/admin expens research interest expens incom net operating- unusu expens incom oper expens total- total oper oper interest incom expens net loss sale assets- incom incom minor interest- equiti affiliates- net incom extra account change- discontinu operations- extraordinari item- net prefer dividends- incom avail common excl extra incom avail common incl extra basic weight averag shares- basic ep exclud extraordinari items- basic ep includ extraordinari items- dilut adjustment- dilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari items- dividend per share common stock primari gross dividend common stock- net incom stock base comp expense- basic ep stock base comp expsense- dilut ep stock base comp expense- depreci supplemental- total special items- normal incom taxes- effect special item incom taxes- incom tax ex impact special items- normal incom taxes- normal incom avail common- basic normal eps- dilut normal actual annual estim annual actual quarterli becton dickinson co march
 short term short term account receiv trade receiv other- total receiv total prepaid current asset total current property/plant/equip total goodwil intang long term long term asset total account accru note payable/short term current port lt debt/capit current liabil total current long term capit leas obligations- total long term total defer incom minor interest- liabil total redeem prefer stock total- prefer stock non redeem common stock addit paid-in retain earn accumul treasuri stock equiti total total liabil sharehold share out common stock primari issue- total common share actual annual actual quarterli balanc sheet item becton dickinson co march
oper activ compar prior-year period
suffici fund oper need chang cash flow oper activ
current-year period also reflect discretionari cash contribut million fund
cash provid invest activ includ million proce busi
capit expenditure-rel cash outflow million compar
million prior-year period focus project enhanc cost structur
manufactur capabl support strategi geograph expans
compani issu debt cash financ activ
period total world-wide cash short-term invest includ restrict cash
approxim billion primarili held jurisdict outsid unit state
month end month end month end month end month end month end month end month end income/start amortization- defer non- chang work oper capit invest item invest financ total dividend issuanc retir stock issuanc retir debt financ foreign exchang net chang interest paid tax paid becton dickinson co march
becton dickinson co deliv strong underli revenu growth
medic life scienc segment continu
remain track carefus cost revenu synergi
compani readi start bard integr activ
quarter result stand-alone basi repres bd combin
bd plu bard result report
total first quarter revenu billion grew currency-neutr
basi result includ impact dispens chang
lower total compani revenu growth basi point exclud
impact drove revenu growth
dilut earn per share compar
prior-year period repres decreas primarili
due restructur transact financ cost associ
acquisit addit tax expens relat new tax legisl
well litig reserv revers prior-year period follow
gross profit margin show increas y/i
compar prior year period includ oper
perform reflect low manufactur cost result
continu oper improv project also includ foreign
currenc translat
sell administr expens percentag revenu
increas sell administr expens percentag
revenu primarili attribut higher ship gener
research develop expens percentag revenu
reflect increas dollar year-over-year reflect
continu commit invest new product platform
revenu billion
grew currency-
share first quarter
compar
prior-
show increas
y/i
compar
prior year
becton dickinson co march
research
develop expens
percentag revenu
reflect
increas
acquisit restructur cost relat acquisit
restructur current year three-month period primarili repres
restructur transact cost incur due acquisit bard
net interest expens compar
increas primarili reflect higher level debt due issuanc
senior unsecur note third quarter
incom tax rate compar
increas effect incom tax rate three-month period fiscal
year attribut certain effect new tax legisl
enact decemb
compar
 revenu growth gener medic segment
incom tax rate
compar
medic procedur solut unit life scienc segment
diagnost system pre-analyt system unit partial off-set
declin revenu pharmaceut system unit due
geographi custom order pattern
also unfavor impact modif dispens equip
leas contract custom medic segment medic
manag solut unit revenu increas
billion compar prior year period
intern revenu reflect increas sale medic
segment medic procedur solut pharmaceut system
unit well growth attribut sale three life scienc
segment unit particularli diagnost system bioscienc unit
revenu billion increas
prior-year period currency-neutr basi
emerg market revenu million compar
million prior year quarter emerg market revenu
current-year period also includ estim million favor impact
due foreign currenc translat
becton dickinson co march
compani organiz structur base upon two princip busi
segment bd medic bd life scienc
growth
billion increas
prior-
revenu growth medic segment unit driven
global sale medic procedur solut unit infus
dispos product also reflect increas intern sale
revenu billion increas
unit revenu
unfavor impact
modif
leas contract
medic manag solut unit revenu
unfavor impact modif dispens equip leas
contract custom
medic segment oper incom driven perform
respect gross profit margin oper expens gross profit margin
higher compar primarili due lower
manufactur cost result continu improv project
enhanc effici oper partial off-set higher raw
sell administr expens percentag revenu
lower compar prior-year period primarili
reflect reduct gener administr cost alloc
research develop expens percentag revenu higher
compar due increas invest new
product platform
becton dickinson co march
world-wide revenu quarter billion increas
prior-year period currency-neutr basi
bd life scienc growth aid flu-rel revenu diagnost
system unit result earlier start flu season comparison
prior year
gross profit margin higher compar primarili
due lower manufactur cost result continu improv
project enhanc effici oper well
favor product mix partial off-set cost associ hurricane-
relat damag product facil puerto rico
sell administr expens percentag revenu
lower compar prior-year period primarili due reduct
gener administr cost alloc segment
research develop expens percentag revenu also
lower compar due lower alloc
total revenu
quarter
billion increas
prior-year
incom life
scienc revenu
becton dickinson co march
integr carefus larg complet day activ bard
success
synergi carefus achiev on-
track achiev bard expect
initi focu public compani procur cost save
revenu synergi carefus activ process product
registr bard revenu synergi expand vascular access
portfolio gain traction detail plan on-going opportun
bd strategi execut toward advanc world health provid
lead medic technolog innov solut drive sustain
healthcar
synergi
carefus
achiev
on-track achiev
bard revenu
synergi expand
gain traction
on-going opportun
medical- improv medic manag across continuum care
lead infect prevent health care safeti
life sciences- enhanc diagnosi infecti diseas cancer
empow research insight insid outsid cell
interventional- advanc manag high burden diseas
enabl surgic intervent procedur
becton dickinson co march
major bard
busi
report new
three
major bard busi report new
intervent segment three organiz unit
intervent segment includ certain legaci bd product platform like
 mueller current report within medic
within medic segment medic procedur solut mp
renam medic deliveri solut md includ bard
vascular access product platform picc midlin
report bard oncolog urolog product group
bd life scienc continu report consist bd legaci
within medic
procedur solut
continu disclos result geograph region unit state
mp renam
solut md
emerg market
bard previous disclos emerg market data
align product sale channel strategi
continu provid visibl growth emerg
becton dickinson co march
sodium chlorid
compound fy
bd venflon bd
bd venflon safeti
bd abseq assay protein
posit system
balloon length sfa
becton dickinson co march
provena famili french dual lumen french singl lumen picc
nautilu delta cathet tip confirm system pediatr port placement
powerglid premium famili reinforc tip powerglid midlin
powerglid selding famili midlin
site rite halcyon ultrasound system enhanc imag qualiti
pma approv lutonix famili drug coat balloon expand
in-stent restenosi long lesion mm lesion length indic
fda approv launch lifestream famili balloon expand stent-graft
treatment iliac arteri stenosi
approv launch new first kind famili fulli implant powerflow
apheresi port provid high flow long term access patient requir chronic
urolog critic
endobeam famili laser fiber
addit size phasix resorb mesh
new configur xenmatrix ab antibiot coat biolog deriv hernia
becton dickinson co march
bp bp
ep
repres
growth
gross profit expect
ep expect
effect tax rate expect
gross profit expect
ep expect
effect tax rate expect
becton dickinson co march
decemb bd complet acquisit bard inc
bard total consider transfer includ cash stock
compani expect adjust dilut earn per share includ
accret bard acquisit
repres growth currency-neutr
world-wide revenu billion increas
prior-year period reflect volum growth almost
favor impact foreign currenc translat partial off-set
rel immateri unfavor price impact
medic segment volum growth driven global sale
medic procedur solut unit intern demand
product pharmaceut system unit
medic manag solut unit revenu
unfavor impact modif dispens equip leas
contract custom prior year impact time
bd complet
acquisit bard
inc bard total
cash stock
revenu
prior-year
flow
oper activ
million
life scienc segment volum growth first quarter driven
growth three organiz unit particularli diagnost
new tax legisl becam effect januari reduc
 feder corpor tax rate
new bd plu bard compani expect currency-neutr revenu growth
compar basi includ bd bard
current prior year period repres strong underli growth
econom environ healthcar industri healthcar
util unit state gener stabil destabil
futur could advers impact busi
becton dickinson co march
non- reconcili
non- reconcili
non- reconcili
oper tax oper tax becton dickinson co march
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co march
revenu growth ttm decreas compar
ep y/i growth declin ttm
oper incom y/i growth declin
gross margin compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth becton dickinson co march
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale becton dickinson co march
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqreturn mrqcapex salescap ex salesfre mrqreturn equiti becton dickinson co march
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item becton dickinson co march
balanc sheet item
outstand equival market properti plant properti plant issuanc prefer issuanc chang becton dickinson co march
averag price-to-earnings price-to-earnings till date expect fall
price-to-earnings averag price-to-earnings move averag
bandp/eaverageavg stdevavg stdev becton dickinson co march
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co march
breakdown share held insid share held float held institut hold direct holder form vincent timothi gari john samrat wilard bertram gari jame institut holdersholdershar report outvaluepric row associ vanguard group inc fmr fundsmith jp morgan well fargo putnam invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard price row growth stock fund spdr etf price row chip growth fund price row capit appreci franklin manag trust rise dividend vanguard institut fund-institut fidel select portfolio medic equip price row becton dickinson co march
compani name/symbolcurr consensuspricetoday changemarketrecommendationcapbecton dickinson sirona minor becton dickinson co march
developmentsbd launch circul cell-fre dna blood collect tube cancer non-invas prenat test applicationsbd announc commerci avail ce-ivd mark paxgen blood ccfdna tube within european econom area switzerland western europ plastic blood collect tube includ proprietari sampl stabil addit bd vacutain hemogard technolog help protect healthcar worker safeti design ensur accur reproduc result molecular diagnost test applic use circul cell-fre dna ccfdna cancer non-invas prenat test fda approv new hpv test detect identifi hpv genotyp put women high risk cervic cancerbd announc receiv pre-market approv food drug administr fda bd onclar hpv assay test detect type high-risk human papillomaviru hpv specimen collect cervic cancer screen pap test bd surepath liquid base cytolog vial bd launch new lo angel counti program equip patient essenti resourc sharp dispos bd launch new la counti program help ensur proper contain dispos household sharp health concern dispos improperli could caus injuri spread infect contain respons dispos card sharp initi provid essenti resourc help patient throughout la counti safe discard use household sharp provid patient new sharp contain devic cost direct nearest sharp take-back locat bd announc complet enrol lutonix drug coat balloon below-the-kne trialth compani announc complet enrol lutonix below-the-kne btk trial plan submit pre-market approv applic late lutonix btk trial on-go dcb trial btk arteri enrol patient past four year februari becton dickinson co march
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
ytd stock perform
bd compar
price-to-earnings ratio bd
industri average
sale ttm growth rate
compani
neg compar
industri
becton dickinson co march
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit becton dickinson co march
consensu view analyst trend stock
growth rate
bd in-
line average
forward price-to-earnings
bd
 average
bdx avgfive-year growth forecast usdgrowth high day day day estim comparisonbdxindustri avg avgprice/earn yield becton dickinson co march
consensu view analyst trend stock
ep averag estim current
quarter next
quarter
sale growth estim
current quarter next
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr becton dickinson co march
price target summarycrispidea isi jamesupgradestrong isi groupupgradeoutperformrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext yearavg estcurr qtr next qtrcurrent yearnext yearavg becton dickinson co march
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co march
stock trade feb stock price went
month jan stock price went around
month return stock
 price movementvolumeclos becton dickinson co march
stock price high annual stock return
march stock trade sept fell
jan stock price went feb went
 price movementvolumeclos becton dickinson co march
year chart show rise price stock
stock averag trade volum rel flat
 year price movementvolumeclos becton dickinson co march
saw good growth busi new product launch innov stock
achiev growth last one year expect acquisit bard drive revenu
maintain buy rate target price
becton dickinson co march
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
